RE: More data...more sales?13 Nov 2025 15:12
You must be posting fake material. Below is the factual truth
renalytix test usa success stories
Success stories for the Renalytix test, KidnetelX, in the USA include improved risk prediction for kidney failure and increased patient engagement. Clinical studies have shown that the test accurately identifies patients at risk for progression to kidney failure and dialysis, with 87% of patients reporting improved understanding of their risk and 98% stating it helped them understand the importance of their health. These results have supported the test's adoption in major health systems and led to more timely and guideline-appropriate treatment decisions, such as prescribing SGLT2 inhibitors.
Clinical outcomes
Improved risk prediction: KidneyIntelX has demonstrated superior performance in predicting progression to kidney failure or dialysis compared to traditional methods like the Kidney Failure Risk Equation (KFRE).
Higher accuracy: When the test identified a patient as not at risk, it was correct 95% of the time. When it identified a patient as at risk, it was correct more than 50% of the time.
Timely action: In a real-world evidence study, 57% of high-risk patients had action taken on their care, such as medication changes or specialist referrals, within three months of testing, compared to only 35% of low-risk patients.
Patient and provider engagement
Increased patient understanding: 87% of patients in a community setting reported that the test improved their understanding of their kidney risk, and 98% found the test helpful for understanding their kidney disease and overall health.
Informed care management: 86% of physicians in a community setting reported that the test results informed their care management decisions.
Guideline-appropriate therapy: Data from Mount Sinai showed that KidneyIntelX testing helped drive guideline-appropriate use of therapies like SGLT-2 inhibitors and timely specialist consultations for high-risk patients.
Broader success metrics
Commercial growth: The company has secured partnerships with major health systems like Mount Sinai, Atrium Health, and Wake Forest Baptist Health, enabling the test's availability at numerous hospitals.
Adoption: Primary care physicians have found the test valuable as a risk-decision tool, with 98% of surveyed physicians confirming its value.
Sign In
Follow the stocks
